Mode
Text Size
Log in / Sign up

Systematic review and meta-analysis of proximal tibia reconstruction after tumor resection reports complication and survival ratesNew analysis shows prosthetic implants work better than biological options for tibia tumor cases

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider prosthetic reconstruction for lower complications but note biological methods have higher failure rates in proximal tibia tumor reconstruction.

This is a systematic review and meta-analysis of proximal tibia reconstruction methods after tumor resection, including megaprostheses, osteoarticular allografts, intercalary allografts, and allograft-prosthetic composites, with a sample of 2,825 patients. The authors synthesized complication rates and implant survival, finding prosthetic reconstruction had the lowest overall complication rate (39.2% vs. OAs 69.6%, APCs 52.7%, ICAs 53.4%; p = 0.004). Biological reconstructions had significantly higher structural failure rates (OA 31.0%, ICA 24.5% vs. prosthesis 5.5%; p < 0.001). Five-year implant survival showed no significant differences (prosthesis 75.3%, OA 67.4%, APC 74.3%), and ten-year survival converged across methods (63%-71%). For extensor mechanism reconstruction, direct tendon-to-metal reattachment resulted in worse extension lag (11.0 degrees) than synthetic augmentation (5.7 degrees), allograft reattachment (4.6 degrees), or autograft reconstruction (2.3 degrees; p < 0.001). The authors note complications were classified using the Henderson system, but limitations include the observational nature of included studies and lack of reported funding or conflicts. Practice relevance suggests considering techniques beyond direct reattachment to optimize extension function, with patient factors guiding method selection.

This study looked at how doctors rebuild the top of the shin bone after removing tumors. They examined nearly three thousand patients who received different types of replacements or grafts. The team tracked how well these repairs worked over many years, with an average follow-up time of over seven years. They also checked how well the knee could straighten after surgery.

Prosthetic replacements showed the best results for avoiding complications. These metal implants had a much lower rate of problems compared to biological options like bone grafts. The biological methods failed more often because the bone did not hold together as well over time. Despite this, the metal implants and biological grafts lasted a similar amount of time in the body.

The study found that how the tendon is reattached matters a lot. Simply tying the tendon directly to the metal implant led to worse knee movement. Using synthetic materials or biological tissue to help connect the tendon worked much better. Doctors should choose the best method for each patient to get the best possible function.

What this means for you:
Prosthetic implants have fewer complications than biological grafts, and surgeons should use special tendon repairs to improve knee movement.

Study Details

Study typeMeta analysis
Sample sizen = 2,825
EvidenceLevel 1
Follow-up310.8 mo
PublishedMay 2026
View Original Abstract ↓
BACKGROUND: Proximal tibia reconstruction after tumor resection is technically challenging due to the dual requirement of skeletal stability and extensor mechanism restoration. Multiple reconstruction methods exist, but comparative data on complications, survival, and functional outcomes remain limited. This study aimed to compare complication rates and implant survival across different proximal tibia reconstruction methods (megaprostheses, osteoarticular allografts [OAs], intercalary allografts [ICAs], and allograft-prosthetic composites [APCs]) and to evaluate how extensor mechanism reconstruction technique influences functional outcomes. METHODS: A systematic review and meta-analysis was performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. PubMed and Embase databases were searched through September 2025. Studies reporting outcomes of proximal tibia and/or extensor mechanism reconstruction for oncologic indications were included. Complications were classified using the Henderson system. Random-effects meta-analysis was performed for complication rates, implant survival, and extension lag. Subgroup analyses were performed by reconstruction type. RESULTS: Seventy-eight studies including 2,825 patients were analyzed (mean age 25.9 years, mean follow-up 84.7 months). Prosthetic reconstruction demonstrated the lowest overall complication rate (39.2%, 95% confidence interval [CI] 32%-45%) compared with OAs (69.6%, 95% CI 55%-82%), APCs (52.7%, 95% CI 32%-73%), and ICAs (53.4%, 95% CI 34%-70%) (p = 0.004). Biological reconstructions had significantly higher structural failure rates (OA 31.0%, ICA 24.5% vs. prosthesis 5.5%, p < 0.001). Five-year implant survival showed no significant differences between prosthesis (75.3%), OA (67.4%), and APC (74.3%). At 10 years, survival rates converged across all methods (63%-71%). Extensor mechanism reconstruction technique significantly influenced extension lag: direct tendon-to-metal reattachment (11.0°) resulted in worse outcomes than synthetic augmentation (5.7°), allograft reattachment (4.6°), or autograft reconstruction (2.3°) (p < 0.001). CONCLUSION: While prosthetic reconstruction offers lower short-term complication rates, long-term implant survival is comparable across reconstruction methods. Extensor mechanism reconstruction technique is a critical determinant of functional outcome. Surgeons should consider techniques beyond simple direct reattachment, particularly synthetic augmentation or biological reconstruction, when feasible to optimize extension function. Individual patient factors should guide selection between prosthetic and biological reconstruction. LEVEL OF EVIDENCE: Level IV. See Instructions for Authors for a complete description of levels of evidence.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.